Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirtazapine for functional dyspepsia with weight loss and depression
ChiCTR-TRC-13003161Phase 4Completed
- Sponsor
- Guangzhou Nansha Central Hospital
- Start
- Apr 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of mirtazapine in functional dyspepsia (FD) and major depressive disorder (MDD) (3 arms), sponsored by Guangzhou Nansha Central Hospital. Primary endpoints: Nepean Dyspepsia Index (NDI) symptom checklist, Hamilton Rating Scale for Depression (HAMD) and 6 more. Started Apr 2013; status: completed.
02
Drugs
mirtazapine
03
Conditions
functional dyspepsia (FD)major depressive disorder (MDD)
Beyond the preview
Go deeper on ChiCTR-TRC-13003161.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-13003161.